Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KP-2027

MPDL3280A-mIgG1-D265A

Home » Antibodies » MPDL3280A-mIgG1-D265A

Background of MPDL3280A-mIgG1-D265A

Atezolizumab, also known as MPDL3280A, a high affinity-specific against PD-L1, is FDA approved for use in metastatic NSCLC after disease progression on platinum-containing chemotherapy. However, as it is a humanized antibody, it is immunogenic in mice. To overcome this issue, MPDL3280A-mIgG1-D265A was generated by recombinant DNA technology . Importantly, its constant region contains a point mutation D265A (a replacement of aspartic acid by alanine at position 265), resulting in the complete loss of cytolytic effector functions.

Specifications

Catalog Number:
KP-2027
Antibody Name:
MPDL3280A-mIgG1-D265A
Isotype:
Mouse-IgG1-D265A, kappa
FC Muations:
Target:
Mouse-PDL1
Species Reactivity:
Human
Host Cell Line:
EXPI-CHO
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Purity:
>95% by SDS-PAGE and SEC-SEC-HPLC
Validation:
SDS-PAGE | SEC-HPLC/  FACS | FACS Blocking | KD
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Stability:

Characterization

Application

References

  1. Cortinovis D, von Pawel J, Syrigos K, et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: safety population analyses from the Ph III study OAK. Ann Oncol 2017;28:v468ÿ96.
  2. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837ÿ46.